Form 4: Mineralys Therapeutics Director, Derek DiRocco, Acquires Stock Options
SEC Form 4 Filing
Director Derek DiRocco acquired stock options in Mineralys Therapeutics, Inc. on February 13, 2025.
Summary
- On February 13, 2025, Derek DiRocco, a director of Mineralys Therapeutics, Inc., acquired 32,900 stock options.
- The options have an exercise price of $10.20.
- The options vest in 12 substantially equal monthly installments following the grant date.
- The options expire on February 13, 2035.
- Following the transaction, DiRocco directly owns 32,900 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency to the market.
Stakeholder Impact
- The granting of stock options could potentially impact shareholders by diluting ownership if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of earliest transaction: acquisition of stock options. |
| 02/13/2035 | Expiration date of the stock options. |
| 02/24/2025 | Date of signature on the Form 4 filing. |
Keywords
Mineralys Therapeutics, Director, Stock Options, Acquisition, Form 4, MLYS, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.